258Tip A Phase II Trial of Loperamide (L) and Granulocyte Colony-Stimulating Factors (G-CSF) to Improve Sacituzumab Govitecan (SG) Tolerance in Patients (pts) with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (mtnbc): PRIMED
ESMO Open(2023)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要